Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors
T. Khanh, Claire Manuszak, Emily M. Thrash, Anita Giobbie‐Hurder, Jiani Hu, Sarah Kelland, Allison Powers, Adrienne de Jonge, Geoffrey I. Shapiro, Mariano Severgnini
Topics & Concepts
MedicineImmune systemOvarian cancerNeutropeniaImmune checkpointInternal medicineImmunologyOncologyCancerCancer researchImmunotherapyChemotherapyCancer Immunotherapy and BiomarkersPARP inhibition in cancer therapyDNA Repair Mechanisms